title: Characterization of the IGF system and analysis of the possible molecular mechanisms leading to IGF-II overexpression in a mesothelioma.
abstract: The expression of members of the IGF system in a mesothelioma from a patient suffering from hypoglycemia, in term placenta and HT29 colon adenocarcinoma cells were compared. Very high levels of IGF-II mRNA and protein were detected in the mesothelioma. Moreover, half of the IGF-II protein took the high-molecular-weight form. We also analyzed the parental imprinting status and the promoter usage of the IGF-II gene. Our results showed loss of imprinting (LOI) in the mesothelioma while the imprinting was maintained in HT29 cells, expressing moderate levels of the transcript. Promoter P4 was active in the three tissues we analyzed, whereas IGF-II mRNA transcription from promoter P3 was only detected in the mesothelioma and the placenta, expressing comparably high levels of the transcript. IGF-II gene structure was identical in the analyzed tissues and cells. The type-I receptor mRNA expression was very low in the tumor. IGFBP-2, -4 and -5 mRNAs were detected in the mesothelioma, while IGFBP-2, -3 and -5 transcripts were detected in the placenta. IGFBP-1 and -6 transcripts were not detected.
authors.affiliation: Départment de Pathologie, Université de Liège, CHU, Sart Tilman, Belgium.
authors.forename: D
authors.initials: D
authors.lastname: Hodzic
authors.forename: L
authors.initials: L
authors.lastname: Delacroix
authors.forename: P
authors.initials: P
authors.lastname: Willemsen
authors.forename: K
authors.initials: K
authors.lastname: Bensbaho
authors.forename: J
authors.initials: J
authors.lastname: Collette
authors.forename: R
authors.initials: R
authors.lastname: Broux
authors.forename: P
authors.initials: P
authors.lastname: Lefèbvre
authors.forename: J J
authors.initials: JJ
authors.lastname: Legros
authors.forename: M
authors.initials: M
authors.lastname: Grooteclaes
authors.forename: R
authors.initials: R
authors.lastname: Winkler
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D015152:Blotting, Northern; D005260:Female; D015870:Gene Expression / Q000235:genetics; D018392:Genomic Imprinting; D019073:HT29 Cells; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000235:genetics; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000235:genetics; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000235:genetics; D018974:Insulin-Like Growth Factor Binding Protein 4 / Q000235:genetics; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000235:genetics; D018976:Insulin-Like Growth Factor Binding Protein 6 / Q000235:genetics; D007335:Insulin-Like Growth Factor II / Q000235:genetics*; D008297:Male; D008654:Mesothelioma / Q000737:chemistry / Q000378:metabolism*; D010920:Placenta / Q000737:chemistry / Q000378:metabolism; D010997:Pleural Neoplasms / Q000737:chemistry / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D012337:RNA, Ribosomal, 18S / Q000032:analysis / Q000235:genetics; D011863:Radioimmunoassay; D017526:Receptor, IGF Type 1 / Q000032:analysis / Q000235:genetics; D013002:Somatomedins / Q000378:metabolism*; D014158:Transcription, Genetic / Q000235:genetics
chemical_list: D018970:Insulin-Like Growth Factor Binding Protein 1; D018971:Insulin-Like Growth Factor Binding Protein 2; D018972:Insulin-Like Growth Factor Binding Protein 3; D018974:Insulin-Like Growth Factor Binding Protein 4; D018975:Insulin-Like Growth Factor Binding Protein 5; D018976:Insulin-Like Growth Factor Binding Protein 6; D012333:RNA, Messenger; D012337:RNA, Ribosomal, 18S; D013002:Somatomedins; D007335:Insulin-Like Growth Factor II; D017526:Receptor, IGF Type 1